Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Third-generation thrombolytic drugs.

M Verstraete1

  • 1Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium.

The American Journal of Medicine
|August 11, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influencing factors in knee kinematics following posteriorly stabilized knee arthroplasty: a comprehensive analysis.

Acta orthopaedica Belgica·2025
Same author

Trends For Smaller Medical Journals.

Acta clinica Belgica·2016
Same author

Temperature dependence of the electronic structure of semiconductors and insulators.

The Journal of chemical physics·2015
Same author

Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.

British journal of cancer·2015
Same author

[Update on the management of acute viral bronchiolitis: proposed guidelines of Grand Ouest University Hospitals].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2013
Same author

[Management of bronchiolitis in general practice and determinants of treatment being discordant with guidelines of the HAS].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2013
Same journal

Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

The American journal of medicine·2026
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric panniculitis.

The American journal of medicine·2026
See all related articles

Third-generation thrombolytic agents show improved angiographic patency in acute myocardial infarction compared to older drugs. However, increased bleeding risk is a potential concern, while mortality rates remain similar in studied cases.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biotechnology

Background:

  • Thrombolytic therapy is crucial for acute myocardial infarction (AMI).
  • Second-generation agents like alteplase have limitations.
  • Development of advanced thrombolytic agents is ongoing.

Purpose of the Study:

  • To review third-generation thrombolytic agents.
  • To compare their efficacy and safety with second-generation agents.
  • To highlight novel mechanisms and origins of these agents.

Main Methods:

  • Literature review of third-generation thrombolytic agents.
  • Comparison of angiographic patency rates.
  • Analysis of bleeding risk and mortality data.
  • Categorization of agents by structure and origin (e.g., antibody conjugates, variants, animal/bacterial molecules).

Related Experiment Videos

Main Results:

  • Third-generation agents demonstrate enhanced fibrin binding and resistance to inhibitors.
  • Agents like monteplase, tenecteplase, reteplase, lanoteplase, pamiteplase, and staphylokinase show higher angiographic patency rates in AMI.
  • Bleeding risk may be increased with these newer agents.
  • Mortality rates in large-scale trials have been comparable to older agents thus far.

Conclusions:

  • Third-generation thrombolytics offer improved reperfusion in AMI.
  • Careful consideration of increased bleeding risk is necessary.
  • Further large-scale trials are needed to fully establish safety and efficacy profiles.